Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer (Q39743590)

14 September 2017

title

Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer (English)

1 reference

14 September 2017

0 references

8

1 reference

14 September 2017

Amin E Moghaddam

9

0 references

Quentin J Sattentau

10

object named as

Quentin J Sattentau

1 reference

14 September 2017

7

John Skehel

1 reference

14 September 2017

George Krashias

1

1 reference

14 September 2017

Anna-Katharina Simon

2

1 reference

14 September 2017

Frank Wegmann

3

1 reference

14 September 2017

Wai-Ling Kok

4

1 reference

14 September 2017

Ling-Pei Ho

5

1 reference

14 September 2017

David Stevens

6

1 reference

14 September 2017

language of work or name

English

0 references

publication date

2 February 2010

1 reference

14 September 2017

1 reference

14 September 2017

volume

28

1 reference

14 September 2017

issue

13

1 reference

14 September 2017

page(s)

2482-2489

1 reference

The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

The rational design of an AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Antibody recognition of a highly conserved influenza virus epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Targeting the innate immune response with improved vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Translating innate immunity into immunological memory: implications for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Immunology of TLR-independent vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Mechanism of action of clinically approved adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Stimulation of humoral antibody formation by polyanions. V. Relationship between enhancement of sheep red blood cell uptake by the spleen and adjuvant action of dextran sulfate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Stimulation of humoral antibody formation by polyanions. I. The effect of polyacrylic acid on the primary immune response in mice immunized with sheep red blood cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Stimulation of humoral antibody formation by polyanions. II. The influence of sulfate esters of polymers on the immune response in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Antibody responses in sheep vaccinated against Staphylococcus aureus mastitis: a comparison of two experimental vaccines containing different adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Persistence of anti-zonae pellucidae antibodies following a single inoculation of porcine zonae pellucidae in the domestic equine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Antigenicity and immunogenicity of equine influenza vaccines containing a Carbomer adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Studies on the primary structure of the influenza virus hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B') recombinant strain in China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Antibody-mediated neutralization and simian immunodeficiency virus models of HIV/AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Induction of CD8+ T cells using heterologous prime-boost immunisation strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Heterologous prime-boost vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Immune therapy for cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Adoptive immunotherapy of cancer using CD4(+) T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Stimulation of humoral antibody formation by polyanions. 3. Restoration of the immune response to sheep red blood cells by polyanions in thymectomized and lethally irradiated mice protected with bone marrow cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Action of dextran sulfate as a direct and general B cell mitogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Activation of murine B cells. II. Dextran sulfate removes the requirement for cellular interaction during lipopolysaccharide-induced mitogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Variation matters: TLR structure and species-specific pathogen recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Polymeric micelles in oral chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

The inhibition of matrix metalloproteinase activity in chronic wounds by a polyacrylate superabsorber

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

In vivo studies of polyacrylate nanoparticle emulsions for topical and systemic applications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

Spray-dried powders of starch and crosslinked poly(acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.046

10.1016/J.VACCINE.2010.01.046

7 January 2021

Identifiers

DOI

1 reference

14 September 2017

1 reference